

19

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 57419

Manuscript Type: META-ANALYSIS

Efficacy and safety ⁴ of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of advance gastric cancer or gastroesophageal junction cancer: A meta-analysis

Li Yang, Xian-Zhe Dong, Xiao-Xuan Xing, Xiao-Hui Cui, Lin Li, Lan Zhang

Abstract

BACKGROUND

Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), researchers have turned toward, with the support of promising clinical trials, anti-PD-1/anti-PD-L1 antibody

Match Overview

7	Internet 33 words crawled on 26-Mar-2020 journals.sagepub.com	1%
8	Internet 34 words crawled on 05-May-2020 www.nature.com	1%
9	Crossref 25 words Minghui Zhang, Yuandi Dong, Haitao Liu, Yan Wang, Shu Zhao, Qijia Xuan, Yan Wang, Qingyuan Zhang. "The clinic	1%
10	Internet 24 words crawled on 06-Apr-2016 www.dovepress.com	1%
11	Crossref 21 words Lujun Chen, Yuqi Xiong, Jing Li, Xiao Zheng, Qi Zhou, Ab bey Turner, Changping Wu, Binfeng Lu, Jingting Jiang. "P	<1%
12	Internet 21 words crawled on 09-May-2020 www.researchsquare.com	<1%
13	Internet 20 words crawled on 26-Jul-2019 www.tandfonline.com	<1%
14	Internet 18 words crawled on 07-Sep-2017 discovery.ucl.ac.uk	<1%
15	Internet 14 words crawled on 12-Jul-2020 www.clinicaltrials.gov	<1%



ALL

IMAGES

VIDEOS

25,100 Results

Any time ▼

The safety and efficacy of anti-PD-1/anti-PD-L1 antibody ...

<https://www.sciencedirect.com/science/article/pii/S2210740119301044>

So far, **anti-PD-1/anti-PD-L1 antibody therapy** is reportedly in treating **gastric cancer** or gastro-oesophageal **junction cancer** (GC/GEJC) in a number of clinical trials. Based on this, we conducted current **meta-analysis** to assess the **safety** and **efficacy of anti-PD-1/anti-PD-L1 antibody** for previously treated advanced GC/GEJC patients.

Cited by: 1

Author: Xiaofei Ni, Yanpeng Xing, Xuan Sun, Jia...

Publish Year: 2020

Efficacy and safety of immune checkpoint inhibitors in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492970>

Introduction. **Gastric cancer** (GC) is an important health problem, being the fifth most common **cancer** and the third leading cause of **cancer** death worldwide, with an estimated 1 000 000 new diagnoses and 783 000 patients died in 2018. 1 Eastern Asia is a high-risk area of GC, the incidence and mortality of GC in China both ranked second, only lower than lung **cancer**. 2 The **gastroesophageal** ...

Clinical Efficacy and Safety of anti-PD-1/PD-L1 Inhibitors ...

<https://pubmed.ncbi.nlm.nih.gov/32034198>

Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for **treatment** of advanced or metastatic **cancer**. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making **treatment**-related decisions difficult. We performed ...

Comparative Efficacy and Safety of Nivolumab and Nivolumab ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033417>

Feb 14, 2020 · **Efficacy and safety** of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: **A systematic review and meta-analysis** of randomized controlled trials. Medicine 96 (26), e7325. 10.1097/MD.0000000000007325 [PMC free article]



ALL

IMAGES

VIDEOS

26,600 Results

Any time ▾

[The safety and efficacy of anti-PD-1/anti-PD-L1 antibody ...](#)

<https://www.sciencedirect.com/science/article/pii/S2210740119301044>

Apr 01, 2020 · So far, **anti-PD-1/anti-PD-L1 antibody therapy** is reportedly in treating **gastric cancer** or **gastro-oesophageal junction cancer** (GC/GEJC) in a number of clinical trials. Based on this, we conducted current **meta-analysis** to assess the **safety and efficacy of anti-PD-1/anti-PD-L1 antibody** for previously treated advanced GC/GEJC patients.

Cited by: 1

Author: Xiaofei Ni, Yanpeng Xing, Xuan Sun, Jian Suo

Publish Year: 2020

[Clinical Efficacy and Safety of anti-PD-1/PD-L1 Inhibitors ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32034198>

Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Wang BC, Zhang ZJ, Fu C, Wang C. Wang BC, et al. Medicine (Baltimore). 2019 Nov;98(47):e18054. doi: 10.1097/MD.00000000000018054.

Cited by: 7

Author: Leitao Sun, Leyin Zhang, Jieru Yu, Yinan Zh...

Publish Year: 2020

[The efficacy and safety comparison of PD-1/PD-L1 antibody ...](#)

<https://apm.amegroups.com/article/view/44031/html> ▾

Introduction. Esophagogastric cancer (EGC) remains an important health issue, of which **gastric cancer** (GC) ranks fifth most prevalent **cancer** globally, with an increase of around 1 million cases in 2018, and **esophageal cancer** (EC) is the seventh, with 0.57 million diagnoses cases in 2018 (). **Gastroesophageal junction cancer** (GEJC) is a type of lethal malignancy at the **junction** between the ...

Author: Chuan Liu, Wancong Wang, Jiahui Yang...

Publish Year: 2020

[Efficacy and safety of neoadjuvant immunotherapy in ...](#)

<https://www.sciencedirect.com/science/article/pii/S074879832030559X>

Jun 24, 2020 · He, et al. **Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis** OncoImmunology, 8 (2019), Article e1581547 Google Scholar

Author: Zhening Zhang, Siyuan Cheng, Jifang G...

Publish Year: 2020

[Improved efficacy of taxanes and ramucirumab combination ...](#)

https://esmoopen.bmj.com/content/4/Suppl_2/e000775 ▾

Jul 01, 2020 · Background The **efficacy and safety** of chemotherapy (CTx) after anti-PD-1 **therapy** in patients with advanced **gastric cancer** (AGC) remains unclear. Methods Medical records of consecutive



53,600 Results Any time ▾

[The safety and efficacy of anti-PD-1/anti-PD-L1 antibody ...](#)

<https://www.sciencedirect.com/science/article/pii/S2210740119301044>

Apr 01, 2020 · So far, **anti-PD-1/anti-PD-L1 antibody therapy** is reportedly in treating **gastric cancer** or **gastro-oesophageal junction cancer** (GC/GEJC) in a number of clinical trials. Based on this, we conducted current **meta-analysis** to assess the **safety** and **efficacy of anti-PD-1/anti-PD-L1 antibody** for previously treated advanced GC/GEJC patients.

Cited by: 1 **Author:** Xiaofei Ni, Yanpeng Xing, Xuan Sun, Jian...

Publish Year: 2020

[Clinical Efficacy and Safety of anti-PD-1/PD-L1 Inhibitors ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32034198>

Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with **gastric or gastroesophageal junction cancer**: a systematic review and **meta-analysis**. Wang BC, Zhang ZJ, Fu C, Wang C. Wang BC, et al. Medicine (Baltimore). 2019 Nov;98(47):e18054. doi: 10.1097/MD.00000000000018054.

Cited by: 8 **Author:** Leitao Sun, Leyin Zhang, Jieru Yu, Yinan ...

Publish Year: 2020

[\[PDF\] Efficacy and safety of immune checkpoint inhibitors in ...](#)

<https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1581547>

Efficacy and safety of immune checkpoint inhibitors in advanced **gastric or gastroesophageal junction cancer**: a systematic review and **meta-analysis** Cong Chen a,b, Fan Zhang , Ning Zhou b,c, Yan-Mei Gu , Ya-Ting Zhang , Yi-Di He a,b, Ling Wang , Lu-Xi Yang a,d, Yang Zhao , and Yu-Min Li a,b,d

Cited by: 8 **Author:** Cong Chen, Fan Zhang, Ning Zhou, Yan-...

Publish Year: 2019

[Efficacy and safety of neoadjuvant immunotherapy in ...](#)

<https://www.sciencedirect.com/science/article/pii/S074879832030559X>

Jun 24, 2020 · He, et al. **Efficacy and safety** of immune checkpoint inhibitors in advanced **gastric or gastroesophageal junction cancer**: a systematic review and **meta-analysis** Oncoimmunology, 8 (2019), Article e1581547 Google Scholar

Cited by: 1 **Author:** Zhening Zhang, Siyuan Cheng, Jifang Go...